Abnormality/NN
of/IN
Oct-1/NN
DNA/NN
binding/NN
in/IN
T/NN
cells/NNS
from/IN
Sjogren/NN
's/POS
syndrome/NN
patients/NNS
./.

Primary/JJ
Sjogren/NN
's/POS
syndrome/NN
(/(
SS/NN
)/)
is/VBZ
an/DT
autoimmune/JJ
rheumatic/JJ
disease/NN
characterized/VBN
by/IN
T/NN
cell/NN
hypoactivity/NN
./.
=====
To/TO
understand/VB
the/DT
diminished/VBN
T/NN
cell/NN
response/NN
to/TO
activation/NN
signals/NNS
,/,
we/PRP
measured/VBD
nucleoprotein/NN
DNA-binding/JJ
activities/NNS
regulating/VBG
gene/NN
expression/NN
during/IN
T/NN
cell/NN
activation/NN
using/VBG
the/DT
electrophoretic/JJ
mobility/NN
shift/NN
assay/NN
./.
=====
Peripheral/JJ
blood/NN
lymphocytes/NNS
from/IN
9/19/CD
SS/NN
patients/NNS
were/VBD
found/VBN
to/TO
be/VB
defective/JJ
in/IN
their/PRP$
ability/NN
to/TO
bind/VB
an/DT
october/NN
sequence/NN
(/(
Oct-1/NN
)/)
./.
=====
This/DT
Oct-1-binding/JJ
phenotype/NN
remained/VBD
stable/JJ
in/IN
culture/NN
for/IN
up/IN
to/TO
3/CD
days/NNS
prior/RB
to/TO
activation/NN
./.
=====
This/DT
abnormality/NN
was/VBD
not/RB
seen/VBN
in/IN
resting/VBG
T/NN
cells/NNS
nor/CC
T/NN
cells/NNS
from/IN
patients/NNS
with/IN
systemic/JJ
lupus/NN
erythematosus/NN
,/,
rheumatoid/JJ
arthritis/NN
(/(
RA/NN
)/)
,/,
or/CC
SS/NN
accompanied/VBN
by/IN
RA/NN
./.
=====
The/DT
SS/NN
Oct-1/NN
DNA-binding/JJ
abnormality/NN
correlated/VBD
significantly/RB
with/IN
an/DT
inability/NN
of/IN
cells/NNS
to/TO
exit/VB
the/DT
Gzero/G1/NN
cell/NN
cycle/NN
phase/NN
when/WRB
stimulated/VBN
in/FW
vitro/FW
./.
=====
Importantly/RB
,/,
nucleoprotein/NN
extracts/NNS
showing/VBG
decreased/VBN
DNA-binding/JJ
activity/NN
had/VBD
normal/JJ
amounts/NNS
of/IN
Oct-1/NN
proteins/NNS
as/IN
determined/VBN
by/IN
immunoprecipitation/NN
,/,
implying/VBG
a/DT
functional/JJ
defect/NN
in/IN
the/DT
Oct-1/NN
protein/NN
./.
=====
Moreover/RB
,/,
defective/JJ
DNA/NN
binding/NN
was/VBD
corrected/VBN
by/IN
treatment/NN
with/IN
acid/NN
phosphatase/NN
./.